vs
Apellis Pharmaceuticals, Inc.（APLS）与UNITED COMMUNITY BANKS INC（UCB）财务数据对比。点击上方公司名可切换其他公司
UNITED COMMUNITY BANKS INC的季度营收约是Apellis Pharmaceuticals, Inc.的1.4倍（$276.5M vs $199.9M），UNITED COMMUNITY BANKS INC净利率更高（30.5% vs -29.5%，领先60.0%），UNITED COMMUNITY BANKS INC同比增速更快（11.6% vs -5.9%），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs 6.2%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
联合社区银行是美国的金融机构，为美国东南部规模领先的全服务金融机构之一，总资产达277亿美元，在阿拉巴马州、佛罗里达州、佐治亚州、北卡罗来纳州、南卡罗来纳州和田纳西州设有200个营业网点，同时也是总部位于南卡罗来纳州的总资产规模最大的银行。
APLS vs UCB — 直观对比
营收规模更大
UCB
是对方的1.4倍
$199.9M
营收增速更快
UCB
高出17.6%
-5.9%
净利率更高
UCB
高出60.0%
-29.5%
两年增速更快
APLS
近两年复合增速
6.2%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $276.5M |
| 净利润 | $-59.0M | $84.3M |
| 毛利率 | — | — |
| 营业利润率 | -25.6% | — |
| 净利率 | -29.5% | 30.5% |
| 营收同比 | -5.9% | 11.6% |
| 净利润同比 | -62.2% | 18.0% |
| 每股收益（稀释后） | $-0.40 | $0.69 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSUCB
| Q1 26 | — | $276.5M | ||
| Q4 25 | $199.9M | $278.4M | ||
| Q3 25 | $458.6M | $276.8M | ||
| Q2 25 | $178.5M | $260.2M | ||
| Q1 25 | $166.8M | $247.7M | ||
| Q4 24 | $212.5M | $250.9M | ||
| Q3 24 | $196.8M | $217.3M | ||
| Q2 24 | $199.7M | $245.3M |
净利润APLSUCB
| Q1 26 | — | $84.3M | ||
| Q4 25 | $-59.0M | $86.5M | ||
| Q3 25 | $215.7M | $91.5M | ||
| Q2 25 | $-42.2M | $78.7M | ||
| Q1 25 | $-92.2M | $71.4M | ||
| Q4 24 | $-36.4M | $75.8M | ||
| Q3 24 | $-57.4M | $47.3M | ||
| Q2 24 | $-37.7M | $66.6M |
营业利润率APLSUCB
| Q1 26 | — | — | ||
| Q4 25 | -25.6% | 40.5% | ||
| Q3 25 | 48.7% | 42.6% | ||
| Q2 25 | -18.6% | 38.6% | ||
| Q1 25 | -50.0% | 36.8% | ||
| Q4 24 | -12.3% | 38.4% | ||
| Q3 24 | -24.0% | 27.5% | ||
| Q2 24 | -14.7% | 35.1% |
净利率APLSUCB
| Q1 26 | — | 30.5% | ||
| Q4 25 | -29.5% | 31.1% | ||
| Q3 25 | 47.0% | 33.0% | ||
| Q2 25 | -23.6% | 30.3% | ||
| Q1 25 | -55.3% | 28.8% | ||
| Q4 24 | -17.1% | 30.2% | ||
| Q3 24 | -29.2% | 21.8% | ||
| Q2 24 | -18.9% | 27.2% |
每股收益（稀释后）APLSUCB
| Q1 26 | — | $0.69 | ||
| Q4 25 | $-0.40 | $0.71 | ||
| Q3 25 | $1.67 | $0.70 | ||
| Q2 25 | $-0.33 | $0.63 | ||
| Q1 25 | $-0.74 | $0.58 | ||
| Q4 24 | $-0.30 | $0.61 | ||
| Q3 24 | $-0.46 | $0.38 | ||
| Q2 24 | $-0.30 | $0.54 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $493.1M |
| 总债务越低越好 | — | $205.5M |
| 股东权益账面价值 | $370.1M | $3.7B |
| 总资产 | $1.1B | $28.2M |
| 负债/权益比越低杠杆越低 | — | 0.06× |
8季度趋势，按日历期对齐
现金及短期投资APLSUCB
| Q1 26 | — | $493.1M | ||
| Q4 25 | $466.2M | — | ||
| Q3 25 | $479.2M | — | ||
| Q2 25 | $370.0M | — | ||
| Q1 25 | $358.4M | — | ||
| Q4 24 | $411.3M | — | ||
| Q3 24 | $396.9M | — | ||
| Q2 24 | $360.1M | — |
总债务APLSUCB
| Q1 26 | — | $205.5M | ||
| Q4 25 | — | $120.4M | ||
| Q3 25 | — | $155.3M | ||
| Q2 25 | — | $155.1M | ||
| Q1 25 | — | $254.3M | ||
| Q4 24 | — | $254.2M | ||
| Q3 24 | — | $316.4M | ||
| Q2 24 | — | $324.9M |
股东权益APLSUCB
| Q1 26 | — | $3.7B | ||
| Q4 25 | $370.1M | $3.6B | ||
| Q3 25 | $401.2M | $3.6B | ||
| Q2 25 | $156.3M | $3.6B | ||
| Q1 25 | $164.2M | $3.5B | ||
| Q4 24 | $228.5M | $3.4B | ||
| Q3 24 | $237.1M | $3.4B | ||
| Q2 24 | $264.3M | $3.3B |
总资产APLSUCB
| Q1 26 | — | $28.2M | ||
| Q4 25 | $1.1B | $28.0B | ||
| Q3 25 | $1.1B | $28.1B | ||
| Q2 25 | $821.4M | $28.1B | ||
| Q1 25 | $807.3M | $27.9B | ||
| Q4 24 | $885.1M | $27.7B | ||
| Q3 24 | $901.9M | $27.4B | ||
| Q2 24 | $904.5M | $27.1B |
负债/权益比APLSUCB
| Q1 26 | — | 0.06× | ||
| Q4 25 | — | 0.03× | ||
| Q3 25 | — | 0.04× | ||
| Q2 25 | — | 0.04× | ||
| Q1 25 | — | 0.07× | ||
| Q4 24 | — | 0.07× | ||
| Q3 24 | — | 0.09× | ||
| Q2 24 | — | 0.10× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | — |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | — |
| 自由现金流率自由现金流/营收 | -7.1% | — |
| 资本支出强度资本支出/营收 | 0.1% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | — |
8季度趋势，按日历期对齐
经营现金流APLSUCB
| Q1 26 | — | — | ||
| Q4 25 | $-14.2M | $384.0M | ||
| Q3 25 | $108.5M | $123.1M | ||
| Q2 25 | $4.4M | $96.8M | ||
| Q1 25 | $-53.4M | $98.6M | ||
| Q4 24 | $19.4M | $349.7M | ||
| Q3 24 | $34.1M | $7.7M | ||
| Q2 24 | $-8.3M | $105.1M |
自由现金流APLSUCB
| Q1 26 | — | — | ||
| Q4 25 | $-14.3M | $356.5M | ||
| Q3 25 | $108.3M | $117.7M | ||
| Q2 25 | $4.4M | $84.7M | ||
| Q1 25 | $-53.4M | $94.3M | ||
| Q4 24 | $19.3M | $302.7M | ||
| Q3 24 | — | $-2.2M | ||
| Q2 24 | $-8.4M | $87.2M |
自由现金流率APLSUCB
| Q1 26 | — | — | ||
| Q4 25 | -7.1% | 128.0% | ||
| Q3 25 | 23.6% | 42.5% | ||
| Q2 25 | 2.5% | 32.6% | ||
| Q1 25 | -32.0% | 38.1% | ||
| Q4 24 | 9.1% | 120.7% | ||
| Q3 24 | — | -1.0% | ||
| Q2 24 | -4.2% | 35.6% |
资本支出强度APLSUCB
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | 9.9% | ||
| Q3 25 | 0.0% | 1.9% | ||
| Q2 25 | 0.0% | 4.7% | ||
| Q1 25 | 0.0% | 1.7% | ||
| Q4 24 | 0.0% | 18.8% | ||
| Q3 24 | 0.0% | 4.6% | ||
| Q2 24 | 0.0% | 7.3% |
现金转化率APLSUCB
| Q1 26 | — | — | ||
| Q4 25 | — | 4.44× | ||
| Q3 25 | 0.50× | 1.35× | ||
| Q2 25 | — | 1.23× | ||
| Q1 25 | — | 1.38× | ||
| Q4 24 | — | 4.61× | ||
| Q3 24 | — | 0.16× | ||
| Q2 24 | — | 1.58× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
UCB
| Deposits | $98.0M | 35% |
| Investment securities, including tax exempt of $1,646 and $1,678, respectively | $45.3M | 16% |
| Money market | $40.7M | 15% |
| Time | $28.7M | 10% |
| NOW and interest-bearing demand | $28.1M | 10% |
| Service charges and fees | $9.5M | 3% |
| Other | $8.0M | 3% |
| Mortgage loan gains and other related fees | $8.0M | 3% |
| Wealth management fees | $4.6M | 2% |
| Lending and loan servicing fees | $4.0M | 1% |
| Deposits in banks and short-term investments | $1.2M | 0% |
| Securities gains, net | $133.0K | 0% |
